|For urgent issues, contact Monique Bertrand at 408-799-1878
|For urgent issues:
OnCore coverage for the following time critical issues:
|Email CCTO-website with any urgent issues. Email box will be monitored.
|The extended absence greeting and automatic reply will notify callers and emailers:
|In the event of an emergency during the closure, please leave a voicemail message at 650-725-0661. Be sure to leave a call-back number. Voicemail will be monitored and your call will be returned.
Please see the following notice about the creation of a new group that will consolidate communications, outreach and marketing for the institute. The CCTO Communications and Outreach groups will align under this group so starting in the new year, Sarah Pelta and Rachel Mesia will transition to report to Whitney. This is a very exciting opportunity for those groups to be involved with important programs and initiatives at the institute level – this will include clinical research but also other cancer programs that align with the institute’s mission and goals.
I am pleased to announce that Whitney Greene-Nymo is joining the Stanford Cancer Institute (SCI) as the new Executive Director of Strategic Communications, Community Outreach and Program Development on Monday, January 8, 2018.
For those who have not had the opportunity to work with Whitney in the past, she joins the SCI leadership team following a nine year tenure at Stanford Health Care (SHC) focused largely on the cancer service line, most recently as the Executive Director of Business Development. Whitney is passionate about all aspects – research, prevention, treatment, education, outreach – of our exciting field of oncology, and her contributions within the Stanford cancer arena are many. On her short list of accomplishments you will find: developing and executing strategies which significantly increased oncology volume and revenue; spearheading SHC’s oncology network development strategy, including the creation of the business plan for Stanford Cancer Center South Bay; and managing the design and construction of the Stanford Women’s Cancer Center. Whitney represents Stanford cancer at a national level as a member of the steering committee of the National Cancer Institute’s Public Affairs and Marketing Network, where she learns and shares best practices with colleagues from NCI-designated cancer centers across the country. Whitney received her MBA from Stanford and her undergraduate degree in mathematics from Duke where she was named to the Phi Beta Kappa honor society.
Our new Executive Director position was created from existing vacancies. Through a central leadership structure, this role will unite and consolidate the current marketing, communications, and community outreach and engagement efforts into one strong and talented team. Goals and objectives will be aligned within the SCI including cancer clinical research, and across the School of Medicine, Stanford Health Care and Lucile Packard Children’s Hospital. Whitney will provide critical strategic oversight for the SCI communications and community outreach efforts with the goal of increasing the SCI’s national and international visibility; positioning the SCI as a leader in basic science, translational and clinical research; and, with her team and in collaboration with others, will execute strategies focused on medically under-served populations in our catchment area. This role joins all of our SCI positions in serving as a steward of valuable SCI resources, and as an ambassador of the SCI both within the SOM, SHC and LPCH, and beyond our local community.
Please join me in welcoming Whitney to the SCI and our leadership team, and in wishing her a long and productive career with the preeminent Stanford Cancer Institute. Whitney can be reached at firstname.lastname@example.org starting in January, and will be reaching out to many of you in her new role and I encourage you to contact her with communication, marketing and community outreach ideas.
We invite you to stop by our suite in the Lokey Building (265 Campus Drive, Suite 2013H) any time to visit in person.
SCI Director of Finance and Administration/Associate Director
Stanford University Paging Services is transitioning all old pager devices to new encrypted pagers for two
- To better secure paged information
- The contract service for old pagers expires in 2018, thus those pagers will not work after
Please read this information sheet to assess whether or not you need to exchange your pager. Instructions on how to exchange your pager can be found on the info sheet. For any additional information or questions please contact Amanda Sullivan.
Earlier this month the FDA approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for the treatment of cancer. Ogivri’s FDA approval is an important step in helping to promote competition that can lower health care costs for breast or metastatic stomach cancer patients.
For more information please read the FDA’s press release.